Aug 14, 2020
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
Jun 22, 2020
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 04, 2020
OncoSec to Present at Virtual Summer Investor Summit
May 21, 2020
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 13, 2020
OncoSec's TAVO(TM) Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma
May 06, 2020
OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
Apr 21, 2020
OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO(TM) Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting
Apr 06, 2020
OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO(TM)
Mar 17, 2020
OncoSec Announces Publication of Positive TAVO(TM) Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncology
Feb 11, 2020
OncoSec Strengthens its Board of Directors with Three New Appointments
Feb 04, 2020
Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue
Feb 03, 2020
OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting
Jan 27, 2020
Data from OncoSec's Visceral Lesion Applicator (VLA) to be Presented at the Society of Interventional Oncology Annual Meeting
Dec 16, 2019
OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program
Dec 05, 2019
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO(TM) and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Nov 26, 2019
OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov 12, 2019
OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO(TM) KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Nov 05, 2019
OncoSec to Present TAVO(TM) Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Sep 26, 2019
OncoSec to Present at the Cantor 2019 Global Healthcare Conference